TPTX - The Take On Turning Point Therapeutics

• After peaking at over $141 in February 2021, shares of Turning Point Therapeutics, Inc. had lost 55% of their value through early October, largely due to a data vacuum.
• That silence was broken on October 7, 2021, with solid, yet short-of-expectations results for its lead candidate (repotrectinib) in a second-line or later setting for ROS1+ NSCLC.
• The Street is still awaiting pivotal additional data for repotrectinib in a frontline setting, where initial data indicated a 90+% ORR for ROS1+ NSCLC.
• With a potentially best-in-class therapy and $1 billion in cash, this precision oncology firm merited a deeper dive.
• A full analysis follows in the paragraphs below.

For further details see: